"杏輝"杏定痛錠100公絲（本補麻隆）

Země: Tchaj-wan

Jazyk: čínština

Zdroj: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Aktivní složka:

BENZBROMARONE

Dostupné s:

杏輝藥品工業股份有限公司 宜蘭縣冬山鄉中山村中山路84、84之4、84之6、84之7號、冬山鄉中山村新寮路95、95之1、100之7、100之13、100之15、100之16、103、136號 (42042734)

ATC kód:

M04AB03

Léková forma:

錠劑

Složení:

BENZBROMARONE (4040000300) 100MG

Jednotky v balení:

鋁箔盒裝;;塑膠瓶裝

Třída:

製　劑

Druh předpisu:

須由醫師處方使用

Výrobce:

杏輝藥品工業股份有限公司 宜蘭縣冬山鄉中山村中山路８４號 TW

Terapeutické oblasti:

benzbromarone

Terapeutické indikace:

痛風、高尿酸血症。

Přehled produktů:

有效日期: 2027/12/26; 英文品名: NOGOUT TABLETS 100MG "SINPHAR"(BENZBROMARONE)

Datum autorizace:

1997-12-26

Informace pro uživatele

PIC/S GMP
( Uricosuric Agent )
Benzbromarone
Benzbromarone..................... 100 mg
Sodium Lauryl Sulfate
Lactose
Starch Potato
Microcrystalline Cellulose
Pyrrolidinone Polymer
Silicon Dioxide Microns
Magnesium Stearate
NOGOUT
Tablets
(Benzbromarone)
100mg
8 4
SINPHAR PHARMACEUTICAL CO., LTD.
84, CHUNG SHAN ROAD, CHUNG SHAN VILLAGE, TUNG - SHAN SHINE, I - LAN,
TAIWAN
[phone]
website
h t t p
//www.sinphar.com
R
PIC/S GMP
Benzbromarone reduces plasma concentration of uric acid probably by
blocking tubular reabsorption and increases urinary uric acid
excretion.
Composition:
Each tablet contains:
Benzbromarone.............................................100mg
Other ingredients
Sodium Lauryl Sulfate
Lactose
Starch Potato
Microcrystalline Cellulose
Pyrrolidinone Polymer
Silicon Dioxide Microns
Magnesium Stearate.
Indications:
Gout, Hyperuricemia.
Dosage and Adminstriation:
The recommended dose is 100mg daily after meals or with meals.
Side effects:
1.Benzbromarone may cause gastro-intestinal side-effects, especially
diarrhoea.
2.Joint pains and acute attacks of gout can occur during initial
treatment
stages, colchicine and anti-inflammatory agents are suggested.
3.Allergic conjunctivitis during benzbromarone administration was
reported.
Precautions:
1.Benzbromarone should be used with caution in patients with impaired
renal function.
2.Benzbromarone was considered to be unsafe in patients with acute
porphyria.
3. An adequate fluid intake is recommended and the pH of the urine
should be adjusted (pH 6.3
6.7) to reduce the risk of renal stones.
4.The use of benzbromarone during pregnancy and breast feeding
is not recommended.
5.Long-term therapeutic patients should have hepatic function tests.
6.Liver function test should be taken prior to the initiation of
Benzbr-
omarone therapy.
7.Suggesting doctors should consider decreasing dosage while offering
this medicine to patients with kidney disorder.
8.Patients with severe hepatic disorder should be more cautious while
taking this medicine.
Interactions:
1.Salicylat